Ocular Manifestations of Familial Transthyretin Amyloidosis

Margaret M. Reynolds, Kevin K. Veverka, Morie Gertz, Angela Dispenzieri, Steven R. Zeldenrust, Nelson Leung, Jose S Pulido

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: Among patients with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type. Patients with TTR amyloidosis have been noted to have ocular, especially vitreous, involvement. In this report, an analysis of the types and frequency of ocular manifestations in TTR amyloidosis is presented. Design: Observational case series. Methods: Two hundred and sixty-three patients who presented to Mayo Clinic with TTR amyloidosis between January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis database maintained by the Department of Hematology. Fifty-four patients had ocular examinations at a mean of 4.25 ± 3.93 months after systemic symptoms. Results: Of 108 examined eyes in 54 patients with TTR amyloidosis, there were 26 eyes (24%) in 13 patients with ocular involvement. Patients with ocular involvement were more likely to be women than those without ocular involvement (46% vs 15%, respectively, P = .008) and have significantly worse visual acuity (VA) at presentation (logMAR 0.24 [Snellen equivalent 20/30] vs logMAR 0.00 [Snellen equivalent 20/20], P = .017). The ophthalmic findings included vitreous amyloid (26/26, 100%), neurotrophic keratitis (2/26, 8%), glaucoma (5/26, 19%), and tortuous retinal vessels (4/26, 15%). The glaucoma was classified as open-angle (2/26), exfoliative (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26). Ten patients underwent vitrectomy for visually significant vitreous amyloidosis, which significantly improved VA from a baseline of logMAR 0.70 (Snellen equivalent 20/100) to logMAR 0.05 (Snellen equivalent ∼20/20), P = .003. Three TTR mutations, Glu89Lys, Gly47Arg, and homozygous Gly6Ser, not previously described, were associated with vitreous amyloid. Conclusion: In this large cohort of patients with TTR amyloidosis, female sex and decreased VA were associated with ocular amyloid. Three mutations that have not been previously reported to have vitreous involvement were described: Glu89Lys, Gly47Arg, and homozygous Gly6Ser.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
DOIs
StateAccepted/In press - 2017

Fingerprint

Eye Manifestations
Familial Amyloidosis
Amyloidosis
Amyloid
Visual Acuity
Prealbumin
Glaucoma
Mutation
Retinal Vein
Amyloidosis, Hereditary, Transthyretin-Related
Retinal Vein Occlusion
Retinal Vessels
Keratitis
Vitrectomy
Hematology

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular Manifestations of Familial Transthyretin Amyloidosis. / Reynolds, Margaret M.; Veverka, Kevin K.; Gertz, Morie; Dispenzieri, Angela; Zeldenrust, Steven R.; Leung, Nelson; Pulido, Jose S.

In: American Journal of Ophthalmology, 2017.

Research output: Contribution to journalArticle

Reynolds, Margaret M. ; Veverka, Kevin K. ; Gertz, Morie ; Dispenzieri, Angela ; Zeldenrust, Steven R. ; Leung, Nelson ; Pulido, Jose S. / Ocular Manifestations of Familial Transthyretin Amyloidosis. In: American Journal of Ophthalmology. 2017.
@article{bd91cacc85e64b66832a9b3564511ca5,
title = "Ocular Manifestations of Familial Transthyretin Amyloidosis",
abstract = "Purpose: Among patients with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type. Patients with TTR amyloidosis have been noted to have ocular, especially vitreous, involvement. In this report, an analysis of the types and frequency of ocular manifestations in TTR amyloidosis is presented. Design: Observational case series. Methods: Two hundred and sixty-three patients who presented to Mayo Clinic with TTR amyloidosis between January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis database maintained by the Department of Hematology. Fifty-four patients had ocular examinations at a mean of 4.25 ± 3.93 months after systemic symptoms. Results: Of 108 examined eyes in 54 patients with TTR amyloidosis, there were 26 eyes (24{\%}) in 13 patients with ocular involvement. Patients with ocular involvement were more likely to be women than those without ocular involvement (46{\%} vs 15{\%}, respectively, P = .008) and have significantly worse visual acuity (VA) at presentation (logMAR 0.24 [Snellen equivalent 20/30] vs logMAR 0.00 [Snellen equivalent 20/20], P = .017). The ophthalmic findings included vitreous amyloid (26/26, 100{\%}), neurotrophic keratitis (2/26, 8{\%}), glaucoma (5/26, 19{\%}), and tortuous retinal vessels (4/26, 15{\%}). The glaucoma was classified as open-angle (2/26), exfoliative (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26). Ten patients underwent vitrectomy for visually significant vitreous amyloidosis, which significantly improved VA from a baseline of logMAR 0.70 (Snellen equivalent 20/100) to logMAR 0.05 (Snellen equivalent ∼20/20), P = .003. Three TTR mutations, Glu89Lys, Gly47Arg, and homozygous Gly6Ser, not previously described, were associated with vitreous amyloid. Conclusion: In this large cohort of patients with TTR amyloidosis, female sex and decreased VA were associated with ocular amyloid. Three mutations that have not been previously reported to have vitreous involvement were described: Glu89Lys, Gly47Arg, and homozygous Gly6Ser.",
author = "Reynolds, {Margaret M.} and Veverka, {Kevin K.} and Morie Gertz and Angela Dispenzieri and Zeldenrust, {Steven R.} and Nelson Leung and Pulido, {Jose S}",
year = "2017",
doi = "10.1016/j.ajo.2017.09.001",
language = "English (US)",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Ocular Manifestations of Familial Transthyretin Amyloidosis

AU - Reynolds, Margaret M.

AU - Veverka, Kevin K.

AU - Gertz, Morie

AU - Dispenzieri, Angela

AU - Zeldenrust, Steven R.

AU - Leung, Nelson

AU - Pulido, Jose S

PY - 2017

Y1 - 2017

N2 - Purpose: Among patients with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type. Patients with TTR amyloidosis have been noted to have ocular, especially vitreous, involvement. In this report, an analysis of the types and frequency of ocular manifestations in TTR amyloidosis is presented. Design: Observational case series. Methods: Two hundred and sixty-three patients who presented to Mayo Clinic with TTR amyloidosis between January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis database maintained by the Department of Hematology. Fifty-four patients had ocular examinations at a mean of 4.25 ± 3.93 months after systemic symptoms. Results: Of 108 examined eyes in 54 patients with TTR amyloidosis, there were 26 eyes (24%) in 13 patients with ocular involvement. Patients with ocular involvement were more likely to be women than those without ocular involvement (46% vs 15%, respectively, P = .008) and have significantly worse visual acuity (VA) at presentation (logMAR 0.24 [Snellen equivalent 20/30] vs logMAR 0.00 [Snellen equivalent 20/20], P = .017). The ophthalmic findings included vitreous amyloid (26/26, 100%), neurotrophic keratitis (2/26, 8%), glaucoma (5/26, 19%), and tortuous retinal vessels (4/26, 15%). The glaucoma was classified as open-angle (2/26), exfoliative (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26). Ten patients underwent vitrectomy for visually significant vitreous amyloidosis, which significantly improved VA from a baseline of logMAR 0.70 (Snellen equivalent 20/100) to logMAR 0.05 (Snellen equivalent ∼20/20), P = .003. Three TTR mutations, Glu89Lys, Gly47Arg, and homozygous Gly6Ser, not previously described, were associated with vitreous amyloid. Conclusion: In this large cohort of patients with TTR amyloidosis, female sex and decreased VA were associated with ocular amyloid. Three mutations that have not been previously reported to have vitreous involvement were described: Glu89Lys, Gly47Arg, and homozygous Gly6Ser.

AB - Purpose: Among patients with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type. Patients with TTR amyloidosis have been noted to have ocular, especially vitreous, involvement. In this report, an analysis of the types and frequency of ocular manifestations in TTR amyloidosis is presented. Design: Observational case series. Methods: Two hundred and sixty-three patients who presented to Mayo Clinic with TTR amyloidosis between January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis database maintained by the Department of Hematology. Fifty-four patients had ocular examinations at a mean of 4.25 ± 3.93 months after systemic symptoms. Results: Of 108 examined eyes in 54 patients with TTR amyloidosis, there were 26 eyes (24%) in 13 patients with ocular involvement. Patients with ocular involvement were more likely to be women than those without ocular involvement (46% vs 15%, respectively, P = .008) and have significantly worse visual acuity (VA) at presentation (logMAR 0.24 [Snellen equivalent 20/30] vs logMAR 0.00 [Snellen equivalent 20/20], P = .017). The ophthalmic findings included vitreous amyloid (26/26, 100%), neurotrophic keratitis (2/26, 8%), glaucoma (5/26, 19%), and tortuous retinal vessels (4/26, 15%). The glaucoma was classified as open-angle (2/26), exfoliative (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26). Ten patients underwent vitrectomy for visually significant vitreous amyloidosis, which significantly improved VA from a baseline of logMAR 0.70 (Snellen equivalent 20/100) to logMAR 0.05 (Snellen equivalent ∼20/20), P = .003. Three TTR mutations, Glu89Lys, Gly47Arg, and homozygous Gly6Ser, not previously described, were associated with vitreous amyloid. Conclusion: In this large cohort of patients with TTR amyloidosis, female sex and decreased VA were associated with ocular amyloid. Three mutations that have not been previously reported to have vitreous involvement were described: Glu89Lys, Gly47Arg, and homozygous Gly6Ser.

UR - http://www.scopus.com/inward/record.url?scp=85030629389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030629389&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2017.09.001

DO - 10.1016/j.ajo.2017.09.001

M3 - Article

C2 - 28911993

AN - SCOPUS:85030629389

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -